Copertina

Correction to “Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS ”

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	International Journal of Cancer
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS
di: Zhiqiang Song, et al.
Pubblicazione: (2024)

Ocular toxicity associated with anti‐HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database
di: Heng Chen, et al.
Pubblicazione: (2024)

Patient‐reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials
di: Bradley D. Menz, et al.
Pubblicazione: (2025)

Tyrosine kinase inhibitors with blinatumomab versus chemotherapy in Philadelphia‐positive acute B‐lymphoblastic leukemia
di: Sebastian M. Stolz, et al.
Pubblicazione: (2025)

Postmarketing adverse events of tamoxifen in male and female patients with breast cancer
di: Chengjie Ke, et al.
Pubblicazione: (2024)

Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor
di: Hao Xiong, et al.
Pubblicazione: (2024)

Immune checkpoint inhibitor‐induced vitiligo: A large‐scale real world pharmacovigilance study
di: Bufu Tang, et al.
Pubblicazione: (2025)

Washed microbiota transplantation alleviates tyrosine kinase inhibitors associated gastrointestinal adverse effects
di: Weihong Wang, et al.
Pubblicazione: (2025)

Increased serum NfL and GFAP levels indicate different subtypes of neurologic immune‐related adverse events during treatment with immune checkpoint inhibitors
di: Christina Schmitt, et al.
Pubblicazione: (2025)

Prelude to malignancy: A gene expression signature in normal mammary gland from breast cancer patients suggests pre‐tumorous alterations and is associated with adverse outcomes
di: Maria Andreou, et al.
Pubblicazione: (2024)

Use of chemotherapy and loco‐regional therapy in stage IA triple‐negative breast cancer and their association with oncologic outcomes: A cancer registry study
di: André Pfob, et al.
Pubblicazione: (2024)

HBcrAg is associated with prognosis of hepatitis B virus‐related hepatocellular carcinoma in patients after hepatectomy undergoing antiviral therapy
di: Jian Liu, et al.
Pubblicazione: (2024)

Characterization of bridging therapies in clinical trials leading to FDA approval of CAR‐T cell therapies
di: Victoria Kaestner, et al.
Pubblicazione: (2025)

MR imaging of breast cancer: Interpretable radiomics analysis to assess treatment response and survival prognosis after neoadjuvant therapy
di: Jie Hou, et al.
Pubblicazione: (2025)

Revealing genes associated with cervical cancer in distinct immune cells: A comprehensive Mendelian randomization analysis
di: Ning Li, et al.
Pubblicazione: (2024)

A comparative analysis of risk factor associations with interval and screen‐detected breast cancers: A large UK prospective study
di: Isobel Barnes, et al.
Pubblicazione: (2024)

A targeting nanoplatform for chemo‐photothermal synergistic therapy of small‐cell lung cancer
di: Moli Yin, et al.
Pubblicazione: (2024)

A phase I clinical trial of sonodynamic therapy combined with radiotherapy for brainstem gliomas
di: Linkuan Huangfu, et al.
Pubblicazione: (2024)

Correction to “Polymorphisms within autophagy‐related genes as susceptibility biomarkers for pancreatic cancer: A meta‐analysis of three large European cohorts and functional characterization”
Pubblicazione: (2025)

Correction to “Natural resistance to cancer: A window of hope”
Pubblicazione: (2024)

Rapid COJEC without myeloablative therapy for high‐risk neuroblastoma
di: Brian H. Kushner, et al.
Pubblicazione: (2025)

CAR ‐T cell therapy: Advancements in clinical applications and laboratory testing
di: Minjeong Nam, et al.
Pubblicazione: (2026)

Antigen escape in CAR ‐T therapy: A tumor microenvironment perspective from hematological to solid tumors
di: Shuai Wang, et al.
Pubblicazione: (2025)

Long‐term risk of major cardiac events in breast cancer patients treated with intensity‐modulated and 3‐dimensional conformal radiotherapy: Secondary analysis of a randomized clinical trial
di: Nam Kyu Kang, et al.
Pubblicazione: (2025)

Tolerability and efficacy of chemosaturation in combination with systemic therapy for metastatic uveal melanoma
di: Patrick Kasteleiner, et al.
Pubblicazione: (2026)

Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer
di: Yong Liu, et al.
Pubblicazione: (2025)

Establishment of patient‐derived organoids for guiding personalized therapies in breast cancer patients
di: Huizi Wu, et al.
Pubblicazione: (2024)

Representation of women in clinical trials supporting FDA‐approval of contemporary cancer therapies
di: Sujay Kalathoor, et al.
Pubblicazione: (2024)

Non‐steroidal anti‐inflammatory drug use and inflammatory markers associated with gallbladder dysplasia: A case–control analysis within a series of patients undergoing cholecystectomy
di: Lorena Rosa, et al.
Pubblicazione: (2024)

Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy
di: Brie‐Anne Mannah, et al.
Pubblicazione: (2025)

Prolonged inhibition of intratumoral mast cells enhances efficacy of low‐dose antiangiogenic therapy
di: Nikolaus Berenbrok, et al.
Pubblicazione: (2024)

A causal inference framework to compare the effectiveness of life‐sustaining ICU therapies—using the example of cancer patients with sepsis
di: João Matos, et al.
Pubblicazione: (2025)

Total neoadjuvant therapy with six versus four cycles of CAPOX in locally advanced rectal cancer: A real‐world study
di: Yan‐qin Lan, et al.
Pubblicazione: (2025)

Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: A phase II study
di: Runbo Zhong, et al.
Pubblicazione: (2025)

Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer
di: Erina Haraguchi, et al.
Pubblicazione: (2025)

Heterogeneous treatment effect of dose‐dense paclitaxel plus carboplatin therapy for advanced ovarian cancer
di: Ayumi Taguchi, et al.
Pubblicazione: (2024)

Reproductive late effects and testosterone replacement therapy in male childhood cancer survivors: A population‐based study (the Fex‐Can study)
di: Anu Haavisto, et al.
Pubblicazione: (2024)

Anti‐Her2 therapy patterns in metastatic breast cancer—Real‐world data suggest undertreatment
di: Kathrine F. Vandraas, et al.
Pubblicazione: (2025)

Clinical efficacy of tumor organoid‐guided cancer therapy for locally advanced unresectable or metastatic breast cancer
di: Ying‐yi Lin, et al.
Pubblicazione: (2024)

Long‐term impact of stressful life events on breast cancer risk: A 36‐year genetically informed prospective study in the Finnish Twin Cohort
di: Elissar Azzi, et al.
Pubblicazione: (2025)